Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
NCT06529406
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Relapsing Multiple Sclerosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Colorado, Denver
- Last updated on ClinicalTrials.gov
- September 18, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- University of Colorado Anschutz Medical Campus · Aurora, CO
Nevada · 1
- Cleveland Clinic · Las Vegas, NV
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.